The Phase III IMpower132 study (NCT02657434) is evaluating the efficacy and safety of atezolizumab in combination with pemetrexed and carboplatin or cisplatin in patients with stage IV non‐squamous NSCLC without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) gene mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.